by Virtus | Jun 28, 2026 | Respiratory Preclinical Research
Respiratory biomarkers have become one of the most valuable tools in modern respiratory drug development. They provide measurable biological indicators that help researchers understand disease progression, evaluate therapeutic responses and improve decision-making...
by Virtus | Jun 28, 2026 | Respiratory Preclinical Research
Translational respiratory research is one of the most important stages in modern respiratory drug development. While preclinical respiratory research provides valuable insight into disease biology and therapeutic efficacy, translational research ensures that these...
by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug discovery is the foundation of every new treatment developed for asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, viral respiratory infections and other lung diseases. Before a medicine reaches clinical trials, researchers...
by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
COPD drug development is one of the most active areas of respiratory research as scientists work to develop new therapies for chronic obstructive pulmonary disease. COPD affects hundreds of millions of people worldwide and remains a leading cause of illness and...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Asthma drug development plays a critical role in improving outcomes for millions of people living with asthma worldwide. Despite significant advances in treatment, asthma remains a complex and highly variable respiratory disease that continues to drive demand for...
